CytoAgents
Pittsburgh, US · Founded 2018 · Delaware corporation · 3 known investors
Find your way into CytoAgents
162 people in our graph share verified history with the CytoAgents team — schools, employers, funds. One of them is your warm intro.
Ken Howardunlockedknows Teresa Whalen, RPh · together at UPMC (overlapped)
×8knows the team · via University of Pittsburgh
×3knows the team · via Baxter International Inc.
CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.
Founders & leadership
TW
Teresa Whalen, RPhinCEOA registered pharmacist, she previously led ExcellenceRx as CEO and spent four years at NTT DATA Global Solutions Corporation as SVP of Strategic Partnerships and Senior Director. She serves on the boards of St. Clair Hospital, the Allegheny Conference on Community Development, and Life Sciences Pennsylvania, and invests through BlueTree Venture Fund and the Next Act Fund, where she co-chairs the investment committee.
CM
Catherine MottNamed on SEC filing
TW
Teresa WhalenChief Executive Officer
AM
Anthony McCarleyNamed on SEC filing
JF
John FriedmanNamed on SEC filing
SM
Stanley MarksNamed on SEC filing
Investors · 3
Also in the syndicate · 1
PCG Capitallead
Reported raises · per SEC filings
Form D private placements$13.1M disclosed across 2 of 3 rounds · 2020–2023
▶$7MraisedMay 2023 · 23 investors · Other Health CareRule 506(b)
▶$7MraisedMay 2023 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Roy PriebExecutive Officer
- Robert L FerrisDirector
- Stanley MarksDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- Catherine MottDirector
- Offering amount
- $15.2M
- Amount sold
- $7M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$6.1MraisedAug 2021 · 23 investors · Other Health CareRule 506(b)
▶$6.1MraisedAug 2021 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Catherine MottDirector
- Teresa WhalenExecutive Officer, Director
- Anthony McCarleyDirector
- John FriedmanDirector
- Stanley MarksDirector
- Offering amount
- $6.5M
- Amount sold
- $6.1M
- Minimum investment
- $10K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapIncyte Corporation5 shared keywordsIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Cullinan Therapeutics5 shared keywordsCullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.
Kyverna Therapeutics4 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Companies competing with CytoAgents for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does CytoAgents do?
- CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.
- Who are CytoAgents's investors?
- CytoAgents's investors include Boston Harbor Angels, Richard King Mellon Foundation.
- How much funding has CytoAgents raised?
- CytoAgents has disclosed $13.1M raised across 2 of its 3 known rounds.
- Where is CytoAgents headquartered?
- CytoAgents is headquartered in Pittsburgh, US.